Synnovation will receive total cash consideration of up to $3 billion, consisting of $2 billion in upfront cash and up to $1 billion in development, regulatory, and commercial milestone payments ...
The FDA has approved a Novartis drug for chronic spontaneous urticaria (CSU), providing patients an oral treatment alternative to currently available injectable medications. The regulatory decision ...
Novartis has struck a front-loaded deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion, securing an asset that could defend its breast cancer franchise from ...
The last time I spoke about Novartis (NVS), it was with a Seeking Alpha article entitled "Novartis: Value Continues To Build With Double-Digit Percentage Growth Products." With respect to this article ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results